How to read the severity tiers
- Contraindicated — Do not combine. The combination is either explicitly contraindicated by the FDA label or universally recognized as unsafe (e.g., two GLP-1 receptor agonists at the same time).
- Serious — Combination is allowed but requires close monitoring or proactive dose adjustment of one of the drugs. The classic example is insulin or a sulfonylurea — both can cause hypoglycemia, and adding a GLP-1 on top requires reducing the dose of the existing diabetes medication before the first GLP-1 dose.
- Moderate — Be aware. The interaction is real but usually does not require dose adjustment. Often involves slowed gastric emptying affecting the absorption rate (not total bioavailability) of an oral medication. Examples: warfarin, levothyroxine, oral contraceptives.
- Minor — Generally no action needed. Either no documented interaction or the effect is clinically irrelevant (e.g., a 30-60 minute delay in acetaminophen onset).
Why GLP-1s have so many gastric-emptying interactions
GLP-1 receptor agonists slow gastric emptying as part of their mechanism of action — that's a major contributor to the satiety effect that produces weight loss. The same mechanism delays the absorption of orally administered medications, most of all after the first doses: after a first tirzepatide dose, the acetaminophen peak arrived about an hour later, and the effect faded with continued dosing. For most drugs, total bioavailability (the area under the curve, AUC) is preserved, so the drug still works, but it may take slightly longer to reach peak concentration. Semaglutide tablets are an exception worth knowing: levothyroxine exposure rose 33% when taken with them. The clinical significance is small for most medications and meaningful only for drugs with a narrow therapeutic window or a time-sensitive onset.
Hypoglycemia risk with insulin and sulfonylureas
The most clinically important GLP-1 interaction is the additive hypoglycemia risk when combined with insulin or a sulfonylurea (glipizide, glyburide, glimepiride). GLP-1s enhance glucose-dependent insulin secretion — meaning they only push insulin when blood sugar is elevated — but adding insulin or a sulfonylurea on top can produce dangerous lows. Every GLP-1 label tells prescribers to consider reducing the insulin or sulfonylurea dose when the GLP-1 is started; the labels do not set a fixed percentage, so your prescriber decides how much. This should be discussed with your prescriber in advance, not after the fact. Our diabetes medication interactions cheat sheet lays these combinations out by drug class.
Oral contraceptives: tirzepatide and Foundayo carry a labeled warning
The FDA labels treat oral birth control differently depending on the GLP-1. Tirzepatide (Mounjaro and Zepbound) carries an explicit Section 7 directive: switch to a non-oral method (IUD, implant, injection, patch, or ring) or add a barrier method for 4 weeks after starting and 4 weeks after each dose increase. Foundayo (orforglipron, the oral GLP-1) carries the same type of directive but for 30 days after starting and 30 days after each dose increase. Semaglutide (Wegovy and Ozempic) is the exception — its label reports no clinically significant change in oral contraceptive (ethinyl estradiol/levonorgestrel) levels, so it does not require backup contraception. Non-oral hormonal methods are not affected by any GLP-1. If you take oral birth control and are starting tirzepatide or Foundayo, discuss a backup strategy with your prescriber before your first dose. Why the labels split this way is explained in our birth control and GLP-1 clarifier.
What this tool is NOT
This is an educational lookup tool, not a clinical decision support system. It is not a substitute for your prescriber, your pharmacist, or a real-time interaction checker built into electronic health records. The database covers the highest-frequency clinically meaningful interactions but is not exhaustive. Always tell every prescriber and pharmacist about every medication you take, including over-the-counter products and supplements, and confirm any specific interaction with them before starting or stopping anything.
References
- 1.Novo Nordisk Inc. WEGOVY (semaglutide) injection and WEGOVY (semaglutide) tablets — US Prescribing Information, Sections 1, 2, 7 and 12.3 (revised 06/2026). FDA Approved Labeling (DailyMed). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
- 2.Novo Nordisk Inc. OZEMPIC (semaglutide) injection — US Prescribing Information, Sections 7 and 12.3. FDA Approved Labeling (DailyMed). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79
- 3.Novo Nordisk Inc. RYBELSUS (semaglutide) tablets and OZEMPIC (semaglutide) tablets — US Prescribing Information, Sections 2.1 and 7. FDA Approved Labeling (DailyMed). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98
- 4.Eli Lilly and Company. ZEPBOUND (tirzepatide) injection — US Prescribing Information, Sections 1, 7 and 12.3. FDA Approved Labeling (DailyMed). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
- 5.Eli Lilly and Company. MOUNJARO (tirzepatide) injection — US Prescribing Information, Sections 7 and 12.3. FDA Approved Labeling (DailyMed). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0
- 6.Eli Lilly and Company. FOUNDAYO (orforglipron) tablets — US Prescribing Information, Sections 1, 2.2, 7 and 12.3. FDA Approved Labeling (DailyMed). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8ac446c5-feba-474f-a103-23facb9b5c62
- 7.European Medicines Agency, Pharmacovigilance Risk Assessment Committee (PRAC). GLP-1 receptor agonists — review of psychiatric adverse events. PRAC Assessment Report. EMA. 2024. https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-8-11-april-2024
Related tools and research
Important disclaimer
This tool is for educational purposes only and does not constitute medical advice. Drug interactions are highly individual and depend on dose, timing, and your overall medication list. Weight Loss Rankings does not provide medical advice, diagnosis, or treatment recommendations. Always consult your prescribing clinician and pharmacist before combining any medication with a GLP-1 receptor agonist.